BR9607310A - Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante - Google Patents
Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinanteInfo
- Publication number
- BR9607310A BR9607310A BR9607310A BR9607310A BR9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- immunisuppressive
- recombinant adenovirus
- combining drugs
- vivo
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9501662A FR2730411B1 (fr) | 1995-02-14 | 1995-02-14 | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
PCT/FR1996/000218 WO1996025177A1 (fr) | 1995-02-14 | 1996-02-12 | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9607310A true BR9607310A (pt) | 1997-11-25 |
Family
ID=9476106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9607310A BR9607310A (pt) | 1995-02-14 | 1996-02-12 | Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante |
Country Status (23)
Country | Link |
---|---|
US (2) | US20030004091A1 (pt) |
EP (1) | EP0809516B1 (pt) |
JP (1) | JPH11500430A (pt) |
KR (1) | KR100402540B1 (pt) |
AT (1) | ATE204481T1 (pt) |
AU (1) | AU717218B2 (pt) |
BR (1) | BR9607310A (pt) |
CA (1) | CA2211039C (pt) |
CZ (1) | CZ258197A3 (pt) |
DE (1) | DE69614668T2 (pt) |
DK (1) | DK0809516T3 (pt) |
ES (1) | ES2163612T3 (pt) |
FI (1) | FI119176B (pt) |
FR (1) | FR2730411B1 (pt) |
GR (1) | GR3036438T3 (pt) |
HU (1) | HU222991B1 (pt) |
IL (1) | IL117116A0 (pt) |
MX (1) | MX9706017A (pt) |
NO (1) | NO320072B1 (pt) |
PT (1) | PT809516E (pt) |
SK (1) | SK282235B6 (pt) |
WO (1) | WO1996025177A1 (pt) |
ZA (1) | ZA961161B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
EP0942747A1 (en) * | 1996-08-26 | 1999-09-22 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
AU1288099A (en) | 1997-10-30 | 1999-05-24 | Cornell Research Foundation Inc. | A method of inhibiting an immune response to a recombinant vector |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
AU5470900A (en) * | 1999-06-08 | 2000-12-28 | Children's Hospital Of Philadelphia, The | Methods for preventing formation of inhibitory antibodies in the setting of genetherapy |
FR2799472B1 (fr) * | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
AU2001259691B2 (en) | 2000-05-12 | 2006-02-16 | Genzyme Corporation | Modulators of TNF-alpha signaling |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US7569217B2 (en) * | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
CA2461905A1 (en) * | 2001-09-27 | 2003-04-10 | Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
ATE520400T1 (de) * | 2002-11-21 | 2011-09-15 | Genzyme Corp | Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung |
ATE493980T1 (de) * | 2002-11-21 | 2011-01-15 | Genzyme Corp | Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung |
JP2007520566A (ja) * | 2004-02-04 | 2007-07-26 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | 自己免疫治療のための抗cd3及び抗原特異的免疫療法 |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5962694A (en) * | 1992-12-31 | 1994-08-15 | Exemplar Corporation | Producing cells for transplantation to reduce host rejection and resulting cells |
AU5965294A (en) * | 1993-01-08 | 1994-08-15 | Exemplar Corporation | An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
-
1995
- 1995-02-14 FR FR9501662A patent/FR2730411B1/fr not_active Expired - Fee Related
-
1996
- 1996-02-12 PT PT96903080T patent/PT809516E/pt unknown
- 1996-02-12 BR BR9607310A patent/BR9607310A/pt not_active Application Discontinuation
- 1996-02-12 DE DE69614668T patent/DE69614668T2/de not_active Expired - Lifetime
- 1996-02-12 KR KR1019970705594A patent/KR100402540B1/ko not_active Expired - Fee Related
- 1996-02-12 US US08/894,246 patent/US20030004091A1/en not_active Abandoned
- 1996-02-12 CZ CZ972581A patent/CZ258197A3/cs unknown
- 1996-02-12 MX MX9706017A patent/MX9706017A/es unknown
- 1996-02-12 DK DK96903080T patent/DK0809516T3/da active
- 1996-02-12 CA CA2211039A patent/CA2211039C/fr not_active Expired - Fee Related
- 1996-02-12 ES ES96903080T patent/ES2163612T3/es not_active Expired - Lifetime
- 1996-02-12 JP JP8524707A patent/JPH11500430A/ja not_active Ceased
- 1996-02-12 AU AU47238/96A patent/AU717218B2/en not_active Ceased
- 1996-02-12 AT AT96903080T patent/ATE204481T1/de active
- 1996-02-12 EP EP96903080A patent/EP0809516B1/fr not_active Expired - Lifetime
- 1996-02-12 HU HU9800635A patent/HU222991B1/hu not_active IP Right Cessation
- 1996-02-12 SK SK1108-97A patent/SK282235B6/sk not_active IP Right Cessation
- 1996-02-12 IL IL11711696A patent/IL117116A0/xx unknown
- 1996-02-12 WO PCT/FR1996/000218 patent/WO1996025177A1/fr not_active Application Discontinuation
- 1996-02-13 ZA ZA961161A patent/ZA961161B/xx unknown
-
1997
- 1997-08-13 NO NO19973724A patent/NO320072B1/no not_active IP Right Cessation
- 1997-08-13 FI FI973323A patent/FI119176B/fi not_active IP Right Cessation
-
2001
- 2001-08-23 GR GR20010400947T patent/GR3036438T3/el unknown
-
2004
- 2004-04-14 US US10/823,682 patent/US20040265276A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9607310A (pt) | Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante | |
UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
HK1026378A1 (en) | Syringe serving also as an ampoule and syringe forcollecting blood. | |
BR9609176A (pt) | Composi-{es de agente biolÄgico | |
MX9706109A (es) | Moleculas de adn, preparacion y utilizacion en terapia genica. | |
SG65061A1 (en) | Drug delivery system for two or more active substances | |
GR3032744T3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
BR9804500B1 (pt) | derivado de amida, referida composição farmacêutica e agente terapêutico. | |
ES2130428T3 (es) | Cristales de insulina asp-b28. | |
AU2832297A (en) | Morphogen treatment for chronic renal failure | |
WO2000030622A3 (de) | Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen | |
PL317105A1 (en) | Compositions containing dna and p53 damaging agents | |
NZ335799A (en) | Improvements in or relating to diagnostic/therapeutic agents | |
MX9805939A (es) | Formas solidas de administracion, de liberacion instantanea y procesos para su produccion. | |
AU2001258638A1 (en) | Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof | |
AU3651595A (en) | Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases | |
IL128768A0 (en) | Transdermal therapeutic system containing oestriol | |
MX9706569A (es) | Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica. | |
MX9800697A (es) | Uso de glicosidos de calendula para el tratamiento de psoriasis. | |
ITRM940545A0 (it) | Preparato ad uso cosmetico e/o farmaceutico, con carbone attivo e sostanze disperdenti. | |
UA30011A (uk) | Спосіб профілактики гострих стресових уражень шлунково-кишкового тракту після порожнинних оперативних втручань |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. |